Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorIndustrial Products
SymbolNASDAQ:CDXS
CUSIP19200510
Phone650-421-8100
Debt
Debt-to-Equity Ratio0.02
Current Ratio1.67
Quick Ratio1.61
Price-To-Earnings
Trailing P/E Ratio-31.40
Forward P/E Ratio-57.78
P/E GrowthN/A
Sales & Book Value
Annual Sales$50.02 million
Price / Sales16.60
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book30.59
Profitability
EPS (Most Recent Fiscal Year)($0.50)
Net Income$-22,990,000.00
Net Margins-36.06%
Return on Equity-87.65%
Return on Assets-42.15%
Miscellaneous
Employees116
Outstanding Shares53,240,000
Codexis (NASDAQ:CDXS) Frequently Asked Questions
What is Codexis' stock symbol?
Codexis trades on the NASDAQ under the ticker symbol "CDXS."
How were Codexis' earnings last quarter?
Codexis, Inc. (NASDAQ:CDXS) posted its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.02. The biotechnology company had revenue of $14.04 million for the quarter, compared to analyst estimates of $13.50 million. Codexis had a negative return on equity of 87.65% and a negative net margin of 36.06%. View Codexis' Earnings History.
What price target have analysts set for CDXS?
4 Wall Street analysts have issued twelve-month price targets for Codexis' stock. Their predictions range from $11.00 to $18.00. On average, they anticipate Codexis' stock price to reach $14.25 in the next twelve months. View Analyst Ratings for Codexis.
Who are some of Codexis' key competitors?
Some companies that are related to Codexis include Sensient Technologies (SXT), Green Plains (GPRE), Westlake Chemical Partners (WLKP), Renewable Energy Group (REGI), FutureFuel (FF), Green Plains Partners (GPP), REX American Resources (REX), Amyris (AMRS), Sino United Worldwide Consolidated (SUIC), Pacific Ethanol (PEIX), Tantech (TANH), China Insonline (WAYS), Aemetis (AMTX), CTD (CTDH) and Gevo (GEVO).
Who are Codexis' key executives?
Codexis' management team includes the folowing people:
- Mr. John J. Nicols, Pres, CEO & Director (Age 54)
- Mr. Gordon T. B. Sangster, Sr. VP & CFO (Age 65)
- Mr. Michael D. A. Aldridge, Sr. VP of Corp. & Strategic Devel. (Age 51)
- Dr. James J. Lalonde, Sr. VP of R&D (Age 57)
- Mr. Achilles Antonio Clement, Director of Latin America
Has Codexis been receiving favorable news coverage?
News headlines about CDXS stock have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Codexis earned a news impact score of 0.17 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 45.71 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Codexis' major shareholders?
Codexis' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (4.33%), Prescott Group Capital Management L.L.C. (2.44%), Wells Fargo & Company MN (2.22%), Lord Abbett & CO. LLC (1.29%), First Light Asset Management LLC (1.19%) and Cortina Asset Management LLC (0.97%). Company insiders that own Codexis stock include Bernard J Kelley, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Patrick Y Yang, Thomas R Baruch, Ventures Fund Vii LP Vivo, Ventures Vii Affiliates F Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Codexis.
Which major investors are selling Codexis stock?
CDXS stock was sold by a variety of institutional investors in the last quarter, including Prescott Group Capital Management L.L.C., Cortina Asset Management LLC, First Light Asset Management LLC and Blair William & Co. IL. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Thomas R Baruch and Ventures Vii Affiliates F Vivo. View Insider Buying and Selling for Codexis.
Which major investors are buying Codexis stock?
CDXS stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Baillie Gifford & Co., Bradley Foster & Sargent Inc. CT, Wells Fargo & Company MN, Spark Investment Management LLC, EAM Global Investors LLC, CIBC World Markets Inc. and Millennium Management LLC. View Insider Buying and Selling for Codexis.
How do I buy shares of Codexis?
Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Codexis' stock price today?
One share of CDXS stock can currently be purchased for approximately $15.70.
How big of a company is Codexis?
Codexis has a market capitalization of $875.80 million and generates $50.02 million in revenue each year. The biotechnology company earns $-22,990,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Codexis employs 116 workers across the globe.
How can I contact Codexis?
Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]
MarketBeat Community Rating for Codexis (CDXS)
MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe CDXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
